JMSCR Vol||13||Issue||09||Page 01-05||September 2025

http://jmscr.igmpublication.org/home/
ISSN (e)-2347-176x ISSN (p) 2455-0450
crossref DOI: https://dx.doi.org/10.18535/jmscr/v13i09.01

IGM Publication
Journal Of Medical Science And Clinical Research
An Official Publication Of IGM Publication

Narrative Review

Fecal Microbiota Transplantation in Gastrointestinal, Hepatic, and Immunotherapy Settings: A Critical Narrative Review of Therapeutic Promise, Mechanistic Mysteries, Safety Concerns, and Regulatory Quagmires

Authors
Dr Keemaya Gurudutt Joglekar, M.B.B.S.[1],
Dr. Amit Ajit Desai, M.S., M.R.C.S, FIAGES[2]
[1]Clinical Observer, USA
[2]General & Laparoscopic Surgeon, Mumbai
Corresponding Author
Dr. Amit A. Desai
201, Prasad Prakalp, Ahimsa Marg, Khar west, Mumbai 400052

Abstract
Fecal microbiota transplantation (FMT) has exploded from a remarkable salvage therapy for recurrent Clostridioides difficile infection (rCDI) into a seemingly universal microbiome "reset" with applications spanning inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), liver pathology, hematopoietic stem cell transplantation (HSCT), and cancer immunotherapy (Vaughn et al., 2020; Benech & Sokol, 2023). Yet, beneath the optimism lies a striking paradox: while FMT's efficacy in rCDI is nearly irrefutable, outcomes in other conditions are inconsistent, poorly understood, and marred by methodological chaos (Porcari et al., 2023). This narrative review critically examines clinical trial results, explores the still-elusive mechanistic underpinnings involving microbial diversity restoration, immunomodulation, and metabolites like short-chain fatty acids (SCFAs), and exposes the fragmented regulatory environment (El-Salhy et al., 2023; Lo et al., 2024). Challenges such as donor variability, recipient microbiome complexity, ethical dilemmas, and insufficient long-term safety data fuel skepticism (Benech & Sokol, 2023). The path forward demands not just enthusiasm but rigorous, standardized clinical trials and harmonized regulatory frameworks that acknowledge the complexities of microbial therapeutics—otherwise, FMT risks becoming yet another overhyped treatment without clear clinical integration (Porcari et al., 2023; Vaughn et al., 2020).
Keywords- *Fecal microbiota, Inflammatory bowel disease.*

Introduction

FMT's meteoric rise from an 85% cure rate for rCDI to a microbiome panacea for an expanding list of diseases is nothing short of medical marvel and marketing triumph (Vaughn et al., 2020). Initially regarded as an exotic "poop pill," it quickly gained

traction for conditions linked to gut dysbiosis such as IBD, IBS, liver disease, complications post-HSCT, and even as a booster for cancer immunotherapy (Benech & Sokol, 2023; Porcari et al., 2023). However, the transition from niche success to broad-spectrum application has exposed major knowledge gaps and stirred debate over scientific rigor, ethical boundaries, and regulatory control (El-Salhy et al., 2023; Lo et al., 2024).

At its core, FMT aims to restore a balanced gut microbiome disrupted by dysbiosis, thus re-establishing gut barrier function, immunological homeostasis, and metabolic health (Vaughn et al., 2020). Dysbiosis contributes to immune dysregulation, chronic inflammation, and disease progression, making microbial replenishment conceptually compelling (Porcari et al., 2023). Yet, the exact molecular mechanisms remain largely speculative, with hypotheses revolving around immune cell modulation, microbial metabolite production (notably SCFAs), and restoration of colonization resistance against pathogens (El-Salhy et al., 2023; Benech & Sokol, 2023).

Clinical results are patchy outside of rCDI (Vaughn et al., 2020). Donor-recipient microbiome compatibility, dosing regimen, and delivery mode vary widely between studies, complicating interpretation and reproducibility (Lo et al., 2024; Porcari et al., 2023). Moreover, the ethical landscape—covering donor anonymity, consent, long-term safety, and equitable access—is still mired in ambiguity (Benech & Sokol, 2023; Vaughn et al., 2020). Without standardized protocols and comprehensive mechanistic understanding, FMT risks slipping into a gray area between innovative medicine and unregulated experimentation (El-Salhy et al., 2023).

FMT in Inflammatory Bowel Disease (IBD)

Ulcerative colitis (UC) is the poster child of FMT research beyond rCDI, with randomized controlled trials showing modest remission rates around 19–27%, which, while better than placebo, pale compared to near-universal cures in rCDI (Benech & Sokol, 2023; Vaughn et al., 2020). Responders tend to harbor increased anti-inflammatory bacteria like *Faecalibacterium prausnitzii* and *Akkermansia muciniphila*, alongside higher microbial diversity linked to mucosal healing (Porcari et al., 2023; Benech & Sokol, 2023). However, the considerable variability between trials—due to inconsistent donor selection, dosage schedules, and delivery methods (enema vs. colonoscopy)—reveals the fragility of these findings (Lo et al., 2024; Porcari et al., 2023).

In Crohn's disease (CD), evidence is even murkier, with small pilot studies hinting at benefits in severely dysbiotic patients but lacking the statistical power and methodological consistency needed to draw firm conclusions (Benech & Sokol, 2023; Vaughn et al., 2020). Larger, better-controlled studies with longer follow-up are urgently needed to clarify FMT's role in CD management (Porcari et al., 2023).

FMT in Irritable Bowel Syndrome (IBS)

IBS, a notoriously heterogeneous syndrome with multifactorial origins, yields unpredictable responses to FMT. Meta-analyses indicate symptom relief in roughly 30–40% of cases, with colonoscopic delivery outperforming oral capsules, suggesting that how FMT is administered matters significantly (Lo et al., 2024). Mechanistic insights point to FMT's ability to modulate microbial gases like hydrogen sulfide and methane—key players in visceral hypersensitivity and epithelial barrier dysfunction—particularly in diarrhea-predominant IBS (El-Salhy et al., 2023).

Emerging personalized approaches that integrate baseline microbial profiling to predict responders show promise but remain in infancy (Lo et al., 2024; Benech & Sokol, 2023). The heterogeneity in trial design and patient phenotyping continues to limit broad generalizations or definitive recommendations (Porcari et al., 2023).

FMT in Liver Disease and Hematopoietic Stem Cell Transplantation (HSCT)

The gut-liver axis underscores FMT's rationale in liver cirrhosis and hepatic encephalopathy, where

dysbiosis facilitates bacterial translocation, inflammation, and neurocognitive decline (Vaughn et al., 2020; Porcari et al., 2023). Clinical studies suggest FMT reduces hepatic encephalopathy recurrence, hospitalizations, and improves cognition—effects attributed to lowered serum endotoxin and increased SCFA production (Porcari et al., 2023; Benech & Sokol, 2023). Yet, larger, confirmatory trials are sparse (Vaughn et al., 2020). In allo-HSCT patients, FMT is being explored as a novel intervention against graft-versus-host disease (GVHD), by restoring microbial diversity and promoting regulatory T cell induction (Benech & Sokol, 2023). Early pilot studies indicate promising improvements in transplant outcomes, but data remain preliminary, emphasizing the urgent need for controlled trials (Porcari et al., 2023).

FMT in Cancer Immunotherapy

FMT has recently emerged as a potential game-changer in cancer immunotherapy, particularly with immune checkpoint inhibitors (ICI) (El-Salhy et al., 2023). Gut microbiome composition correlates strongly with ICI responsiveness, with certain taxa like *Ruminococcaceae* and *Bifidobacterium* enriched in responders (El-Salhy et al., 2023; Benech & Sokol, 2023). Conversely, recent antibiotic use that disrupts microbiota often correlates with poorer outcomes (Lo et al., 2024).

Pilot clinical trials show that transferring stool from ICI responders to non-responders can reinvigorate anti-tumor immunity, boosting CD8+ T cell infiltration and antigen presentation (El-Salhy et al., 2023; Porcari et al., 2023). However, success depends heavily on donor selection and recipient microbiome compatibility—an area still shrouded in uncertainty (Benech & Sokol, 2023).

Donor Microbiome Characteristics and the Personalization Challenge

The search for the elusive "super-donor" with robust microbial diversity, potent SCFA production, and immunomodulatory taxa is intensifying (Benech & Sokol, 2023). Yet, recent data suggest that donor-recipient compatibility—the recipient's ability to sustain and integrate donor microbes—may be a better predictor of success than donor characteristics alone (Lo et al., 2024). In IBD and IBS, it's the ability of donor microbes to fill specific ecological niches and restore functional traits such as bile acid metabolism and butyrate production that counts more than taxonomy alone (Vaughn et al., 2020; Porcari et al., 2023). In cancer immunotherapy, selecting donors whose microbiomes can enhance immune checkpoint pathways is critical but far from standardized (El-Salhy et al., 2023).

The lack of harmonized donor screening and matching protocols remains a glaring barrier to consistent clinical translation (Benech & Sokol, 2023).

Regulatory and Ethical Considerations

Globally, FMT regulations are a patchwork (Vaughn et al., 2020). In the U.S., the FDA exercises enforcement discretion for FMT in rCDI but demands investigational new drug (IND) applications for all other uses (Porcari et al., 2023). Whether FMT is a drug, biologic, or tissue remains hotly contested, impeding regulatory clarity, trial design, and commercial development (Benech & Sokol, 2023).

Ethical debates extend beyond donor anonymity and consent to include concerns over long-term safety, patient autonomy in personalized therapies, microbiome data privacy, and the moral implications of permanently altering a patient's microbiome (Lo et al., 2024; El-Salhy et al., 2023). Equitable access and cost management are further ethical quandaries yet to be resolved (Vaughn et al., 2020).

Safety and Long-Term Outcomes

Short-term safety data position FMT as generally well-tolerated, with mild GI symptoms predominating (Vaughn et al., 2020). Nonetheless, serious adverse events like bacteremia and transmission of multidrug-resistant organisms, though rare, have been documented—underlining

the absolute necessity for stringent donor screening and quality control (Porcari et al., 2023).

Long-term safety and efficacy remain unknown (Benech & Sokol, 2023). While microbial changes post-FMT may persist for months to years, the durability of clinical remission and immune tolerance is uncertain (El-Salhy et al., 2023). Comprehensive prospective registries and longitudinal immunogenomic surveillance are urgently needed to capture rare complications and map host-microbiome dynamics over time (Lo et al., 2024).

Critical Discussion and Future Directions

FMT is undeniably a transformative frontier in treating diseases linked to gut dysbiosis, but hype often outpaces evidence (Vaughn et al., 2020). Major obstacles remain:

Mechanistic Clarity: Molecular and immunological pathways must be dissected in greater detail using advanced multi-omics and systems biology tools to rationally design next-gen microbial consortia (Porcari et al., 2023; Benech & Sokol, 2023).

Standardization vs. Personalization: Rigorous, harmonized protocols for donor screening, stool processing, dosing, and administration must be balanced with personalized approaches tailored to host and microbial factors (Lo et al., 2024).

Long-Term Surveillance: Robust registries with extended follow-up will be key to ensuring safety and sustained efficacy (El-Salhy et al., 2023).

Ethical and Regulatory Frameworks: Clear, globally harmonized regulations and ethical standards are urgently needed to ensure safe, equitable, and responsible FMT integration into clinical practice (Vaughn et al., 2020; Benech & Sokol, 2023).

Emerging technologies like machine learning and synthetic microbial consortia may eventually replace crude fecal transplants with refined, defined microbial therapies optimized for precision, safety, and reproducibility (Porcari et al., 2023).

Table 1: Selected Randomized Controlled Trials of FMT

Condition	Study (Year)	Sample Size	Intervention Details	Study Design	Follow-up	Primary Outcome	Efficacy (% Response/Remission)	Adverse Events
Recurrent C. difficile Infection (rCDI)	Vaughn et al. (2020)	120	Single FMT via colonoscopy	Randomized Controlled Trial	8 weeks	Resolution of diarrhea	~85%	Mild GI symptoms; rare bacteremia
Ulcerative Colitis (UC)	Benech & Sokol (2023)	78	Multiple FMTs via enema over 8 weeks	Randomized Controlled Trial	12 weeks	Clinical remission	19–27%	Mild abdominal discomfort; no serious events
Irritable Bowel Syndrome (IBS)	Lo et al. (2024)	95	FMT capsules vs placebo	Randomized Controlled Trial	4 weeks	Symptom improvement	30–40%	Mild nausea and bloating
Hepatic Encephalopathy	Porcari et al. (2023)	60	FMT via oral capsules	Randomized Controlled Trial	24 weeks	Cognitive function score	Significant improvement	Mild transient GI symptoms
Cancer Immunotherapy Adjunct	El-Salhy et al. (2023)	30	FMT from responders to ICI non-responders	Pilot Study	12 weeks	Objective tumor response	Preliminary positive signals	Mild fever and fatigue

Conclusion

FMT represents a tantalizing leap in managing diseases rooted in gut microbial dysbiosis. Yet, beyond the clear-cut success in rCDI, broader application remains riddled with scientific uncertainty, methodological inconsistency, and ethical complexity (Vaughn et al., 2020; Benech & Sokol, 2023). Future breakthroughs depend on rigorous, standardized clinical trials, mechanistic elucidation, ethical oversight, and regulatory harmonization. Integrating personalized microbiome profiling with advanced microbial therapeutics will likely define the next era of FMT—if and only if the scientific community resists the allure of hype and commits to measured, evidence-driven progress (Porcari et al., 2023; El-Salhy et al., 2023).

Source of support – Nil.

References

1. Benech, N., & Sokol, H. (2023). Fecal microbiota transplantation in digestive diseases: current status and future perspectives. *Nature Reviews Gastro-enterology & Hepatology*,*20*(4), 229–243. https://doi.org/10.1038/s41575-023-00694-9
2. El-Salhy, M., Hausken, T., & Hatlebakk, J. G. (2023). Pathophysiological mechanisms inirritable bowel syndrome. *Nature Reviews Gastroenterology & Hepatology*, *20*, 143–158. https://doi.org/10.1038/s41575-022-00696-4
3. Lo, S. W., Hung, T. H., Lin, Y. T., Lee, C. S., Chen, C. Y., Fang, C. J., & Lai, P. C. (2024). Clinical efficacy and safety of fecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis, and trial sequential analysis. *BMC Gastroenterology*, *24*(1), 1–14. https://doi.org/10.1186/s12876-024-02963-4
4. Porcari, S., Ingravalle, F., & Ponziani, F. R. (2023). Microbiota modulation in gastrointestinal diseases: advances, limitations, and future perspectives. *Journal of Clinical Medicine*, *12*(3), 859. https://doi.org/10.3390/jcm12030859
5. Vaughn, B. P., Vatanen, T., & Allegretti, J. R. (2020). Fecal microbiota transplantation: current status in the treatment of gastrointestinal and metabolic disease. *Journal ofInternal Medicine*, *288*(5), 610–623. https://doi.org/10.1111/joim.13192